MindWalk Holdings

HYFT

Market cap $75.7M

MindWalk Holdings (HYFT) has pivoted to an asset-light, AI-driven techbio platform, leveraging its HYFT and LensAI technologies for in silico drug discovery. LensAI's early successes include a dual-action GLP-1 agonist and a universal dengue vaccine candidate, highlighting HYFT's practical potential and commercial promise. HYFT reported record quarterly sales, improved margins, and a strengthened balance sheet post-divestiture.

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company today announced the appointment of industry veteran Thomas W. Lynch, Ph.D. as Chief Business Officer (CBO), effective October 20, 2025. “Tom's combination of biotech depth and software commercialization expertise directly supports MindWalk's next path of growth,” said Dr. Jennifer Bath CEO of MindWalk. “As we expand the reach of our HYFT-powered Deep Data platfo.

MindWalk Holdings Corp. (NASDAQ:HYFT ) ImmunoPrecise Antibodies Ltd. - Shareholder/Analyst Call October 9, 2025 1:00 PM EDT Company Participants Jennifer Bath - CEO, President & Non-Independent Director Presentation Operator Ladies and gentlemen, thank you for standing by.

AUSTIN, Texas--(BUSINESS WIRE)---- $hyft #AI--MindWalk Holdings Corp. (“MindWalk” or the “Company”) (NASDAQ: “HYFT”), a bio-native AI company, today announced that to underscore its confidence in MindWalk's future development and growth prospects, its Board of Directors (the “Board”) has authorized a share repurchase program under which MindWalk may repurchase up to 2.3 million common shares of the Company, no par value (the “Common Shares”) over the twelve-month period commencing on October 15th, 2025, and.

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced a major advancement of its AI-designed GLP-1 therapeutics program. New insights from the Company's LensAI™ platform reveal a previously unrecognized connection between GLP-1 biology and a second, non-overlapping pathway central to healthy aging and systemic resilience. The findings support a first-in-class dual-pathway regimen in which MindWalk'.

MindWalk Holdings Corp. (NASDAQ:HYFT ) Q1 2026 Earnings Call September 15, 2025 10:30 AM EDT Company Participants Jennifer Bath - CEO, President & Non-Independent Director Joseph Scheffler - Interim Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and thank you for joining us today for MindWalk's First Quarter Fiscal 2026 Earnings Call.

MindWalk Holdings Corp. (HYFT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.11 per share a year ago.

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk™”, “Company”, “we” or “us”) (NASDAQ: HYFT), a Bio-Native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced financial results for its first fiscal quarter of 2026, ended July 31, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. First Quarter Highlights: Record revenue of $7.6 million, up 45% year-over-year; continued operations revenue of $3.2 milli.